Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ishioka SI et al. – Planned delay in treatment to allow for fetal maturity is acceptable in pregnant patients with certain types of invasive gynecologic cancers.

Related Articles

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations
Climacteric, 11/16/09    Relevance Score: 69%

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09    Relevance Score: 68%

Endometrial Cancer
American Family Physician, 11/12/09    Relevance Score: 67%

The Impacts of ERCC1 Gene Exon VIII Alternative Splicing on Cisplatin-Resistance in Ovarian Cancer Cells
Cancer Investigation, 10/26/09    Relevance Score: 67%

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09    Relevance Score: 67%

Today in Gynecologic Oncology...keeping you current

Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09

Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09

Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address